Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical (NASDAQ:PROF) announced management will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
Rhea-AI Summary
Profound Medical (NASDAQ:PROF) announced management will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the company website under the Investors IR Calendar.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PROF
On Apr 14, the day this news came out, PROF closed 0.16% below the previous close.
Data tracked by StockTitan Argus for the Apr 14 session.
Key Figures
- Shelf registration size
- $150,000,000
- Form S-3 shelf filed Nov 13, 2025
- Q4 2025 revenue
- $6.0M
- Fourth quarter 2025 results
- Full-year 2025 revenue
- $16.1M
- FY 2025 financial results
- Year-end 2025 cash
- $59.7M
- Cash as of Dec 31, 2025
- Full-year 2025 net loss
- $42.6M
- FY 2025 GAAP results
- TULSA-PRO installed base
- 78 systems
- As reported in Q4/FY 2025 release
- Pipeline potential systems
- 110 systems
- Qualified TULSA-PRO pipeline in Q4/FY 2025
- Equity financings
- $42.45M
- Closed in Dec 2025
Historical Context
-
TULSA-PRO featured in multiple presentations at SIR 2026 in Toronto.
-
Texas Prostate reached 100th TULSA Procedure with 500% volume increase post-Medicare.
-
CAPTAIN trial met primary safety endpoint favoring TULSA over radical prostatectomy.
-
Planned CAPTAIN data call and participation in the ROTH investor conference.
-
Record 2025 revenue but sizeable net loss and equity financings triggered sharp drop.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mri-guided medical
ablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "IR Calendar" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.